[HTML][HTML] Auger electrons for cancer therapy–a review

A Ku, VJ Facca, Z Cai, RM Reilly - EJNMMI radiopharmacy and chemistry, 2019 - Springer
Abstract Background Auger electrons (AEs) are very low energy electrons that are emitted
by radionuclides that decay by electron capture (eg 111 In, 67 Ga, 99m Tc, 195m Pt, 125 I …

[HTML][HTML] Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials

BJ Monk, T Enomoto, WM Kast, M McCormack… - Cancer treatment …, 2022 - Elsevier
Cervical cancer constitutes a significant health burden for women globally. While most
patients with early-stage disease can be cured with radical surgery or chemoradiotherapy …

MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study

R Pötter, K Tanderup, MP Schmid… - The Lancet …, 2021 - thelancet.com
Background The concept of the use of MRI for image-guided adaptive brachytherapy
(IGABT) in locally advanced cervical cancer was introduced 20 years ago. Here, we report …

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

BJ Monk, T Toita, X Wu, JCV Limón… - The Lancet …, 2023 - thelancet.com
Background Concurrent chemoradiotherapy has been the standard of care for locally
advanced cervical cancer for over 20 years; however, 30–40% of treated patients have …

Cervical cancer

PA Cohen, A Jhingran, A Oaknin, L Denny - The Lancet, 2019 - thelancet.com
Each year, more than half a million women are diagnosed with cervical cancer and the
disease results in over 300 000 deaths worldwide. High-risk subtypes of the human …

Systemic therapy in cervical cancer: 30 years in review

M Liontos, A Kyriazoglou, I Dimitriadis… - Critical reviews in …, 2019 - Elsevier
Advanced-inoperable cervical cancer is a challenging entity due to increased percentage of
locoregional and distant recurrences. Furthermore, recurrent cervical cancer not amenable …

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT …

D Lorusso, Y Xiang, K Hasegawa, G Scambia, M Leiva… - The Lancet, 2024 - thelancet.com
Background Pembrolizumab has shown efficacy in persistent, recurrent, or metastatic
cervical cancer. The effect of chemoradiotherapy might be enhanced by immunotherapy. In …

Global challenges of radiotherapy for the treatment of locally advanced cervical cancer

JS Mayadev, G Ke, U Mahantshetty… - International Journal of …, 2022 - ijgc.bmj.com
Cervical cancer represents a significant portion of the global cancer burden for women, with
low-and middle-income countries carrying the bulk of this burden. Additionally, underserved …

Advances in immunotherapy for cervical cancer: recent developments and future directions

MV Sherer, NV Kotha, C Williamson… - International Journal of …, 2022 - ijgc.bmj.com
There is an unmet need for novel therapies to improve clinical outcomes for patients with
locally advanced, recurrent, or metastatic cervical cancer. Most cases of cervical cancer are …

Image guidance in radiation therapy for better cure of cancer

V Grégoire, M Guckenberger… - Molecular …, 2020 - Wiley Online Library
The key goal and main challenge of radiation therapy is the elimination of tumors without
any concurring damages of the surrounding healthy tissues and organs. Radiation doses …